Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy - A secondary analysis of irish clinical oncology research group 97-01

International Journal of Radiation Oncology Biology Physics

Volumn 85, Issue 1, 2013, Pages 101-108

  Mydin, Aminudin R ^a   Dunne, Mary T ^b   Finn, Marie A ^b   Armstrong, John G ^b  

^a HOSPITAL KUALA LUMPUR   (Malaysia)

^b ST LUKE S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL FAILURE; CLINICAL ONCOLOGY; COX REGRESSION; DISTANT METASTASIS; HORMONAL THERAPY; INITIAL TREATMENT; KAPLAN-MEIER; MULTI VARIATE ANALYSIS; NEOADJUVANT HORMONAL THERAPY; OVERALL SURVIVAL; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; PSA DOUBLING TIME; RANDOMIZED TRIAL; RESEARCH GROUPS; TIME POINTS;

DISEASES; ONCOLOGY; RADIOTHERAPY; REGRESSION ANALYSIS; UROLOGY;

PATHOLOGY;

BICALUTAMIDE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISTANT METASTASIS; DOSAGE SCHEDULE COMPARISON; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; TREATMENT DURATION; TREATMENT FAILURE;

ADENOCARCINOMA; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84871377888     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.03.001     Document Type: Article

References (22)

1. M.V. Pilepich, R. Caplan, and R.W. Byhardt Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31 J Clin Oncol 15 1997 1013 1021 (Pubitemid 27106285)
2. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103 106
3. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978 (Pubitemid 46606211)
4. C.J. Ryan, and E.J. Small Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate J Clin Oncol 23 2005 8225 8231 (Pubitemid 46211559)
5. J.G. Armstrong, C.M. Gillham, and M.T. Dunne A randomized trial (Irish Clinical Oncology Research Group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 81 2011 35 45
6. American Society for Therapeutic Radiology and Oncology Consensus statement. Guideline for PSA following radiation therapy Int J Radiat Oncol Biol Phys 37 1997 1035 1041
7. T. Pickles, C. Kim-Sing, and W.J. Morris Evaluation of the Houston biochemical relapse definition in men treated with prolonged neo-adjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias Int J Radiat Oncol Biol Phys 57 2003 11 18 (Pubitemid 36959733)
8. M. Roach, G. Hanks, and H. Thames Defining biochemical failure following radiotherapy with or without hormone therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference Int J Radiat Oncol Biol Phys 65 2006 965 974
9. A.V. D'Amico, K. Cote, and M. Loffredo Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer J Clin Oncol 20 2002 4567 4573 (Pubitemid 35402960)
10. A. Patel, F. Dorey, and J. Franklin Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen J Urol 158 1997 1441 1445 (Pubitemid 27391215)
11. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
12. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
13. D.R. Cox, and E.J. Snell Analysis of Binary Data 2nd ed. 1989 Chapman & Hall London
14. J.W. Denham, A. Steigler, and C. Wilcox Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer 115 2009 4477 4487
15. T.C. Tenenholz, C. Shields, and V.R. Ramesh Survival benefit for early hormone ablation in biochemically recurrent prostate cancer Urol Oncol 25 2007 101 109 (Pubitemid 46349744)
16. W.U. Shipley, M. Desilvio, and M.V. Pilepich Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: a secondary analysis of RTOG protocol 86-10 Int J Radiat Oncol Biol Phys 64 2006 1162 1167
17. L. Souhami, K. Bae, and M. Pilepich Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31 Int J Radiat Oncol Biol Phys 78 2010 1301 1306
18. C.I. Sartor, M.H. Strawderman, and X.H. Lin Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy Int J Radiat Oncol Biol Phys 38 1997 941 947 (Pubitemid 27353672)
19. B. Seruga, and I.F. Tannock Intermittent androgen blockade should be regarded as standard therapy in prostate cancer Nat Clin Pract Oncol 5 2008 574 576
20. G.M. Duchesne, R. Syme, and D. Howell How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer J Clin Oncol 24 2006 2964 (Pubitemid 46630601)
21. C.A. Thompson, T.D. Shanafelt, and C.L. Loprinzi Andropause: symptom management for prostate cancer patients treated with hormonal ablation Oncologist 8 2003 474 487 (Pubitemid 37238876)
22. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456 (Pubitemid 46630983)